The Centers for Medicare and Medicaid Services is presenting its requirement that Medicare coverage for Alzheimer’s drugs will be conditioned on sponsors conducting registry-based studies as significantly less onerous than its earlier proposed randomized clinical trial requirement – and it is.
But that doesn’t mean the criteria CMS outlines for the registry studies will be easy to meet, former CMS chief medical officer Sean Tunis told the Pink Sheet.